Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.96M | 4.56M | 5.19M | 5.55M | 5.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.73M | 5.22M | 6.74M | 9.25M | 12.90M |
| Operating Income | -5.73M | -5.22M | -6.74M | -9.25M | -12.90M |
| Income Before Tax | -5.58M | -4.99M | -6.46M | -8.92M | -12.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.58 | -4.99 | -6.46 | -8.92 | -12.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.58M | -4.99M | -6.46M | -8.92M | -12.54M |
| EBIT | -5.73M | -5.22M | -6.74M | -9.25M | -12.90M |
| EBITDA | -5.73M | -5.21M | -6.73M | -9.24M | -12.88M |
| EPS Basic | -7.42 | -8.19 | -12.64 | -21.71 | -36.31 |
| Normalized Basic EPS | -4.63 | -5.12 | -7.90 | -13.57 | -22.69 |
| EPS Diluted | -7.42 | -8.19 | -12.64 | -21.71 | -36.31 |
| Normalized Diluted EPS | -4.63 | -5.12 | -7.90 | -13.57 | -22.69 |
| Average Basic Shares Outstanding | 3.85M | 2.90M | 2.09M | 1.83M | 1.60M |
| Average Diluted Shares Outstanding | 3.85M | 2.90M | 2.09M | 1.83M | 1.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |